Gregory M. Glenn, President, R&D at NOVAVAX INC (NVAX), sold 3,184 shares at $172.38 ($546K) on 2021-12-15, disclosed to the SEC on 2021-12-16.
Scheduled sale ($546k) by President, R&D under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $168.43 | 1,498 | $252K | 46.2% |
| 2 | $168.82 | 117 | $20K | 3.6% |
| 3 | $170.46 | 213 | $36K | 6.7% |
| 4 | $171.47 | 254 | $44K | 8.0% |
| 5 | $172.38 | 248 | $43K | 7.8% |
| 6 | $173.29 | 91 |
| $16K |
| 2.9% |
| 7 | $174.65 | 137 | $24K | 4.4% |
| 8 | $175.89 | 67 | $12K | 2.2% |
| 9 | $176.83 | 223 | $39K | 7.2% |
| 10 | $178.99 | 103 | $18K | 3.4% |
| 11 | $179.58 | 206 | $37K | 6.8% |
| 12 | $180.62 | 27 | $5K | 0.9% |
| Total | $171.45 avg | 3,184 | $546K | 100% |
| Filing → |
| NVAX | SELL | 2021-12-02 | $3.2M | — | Filing → |
| NVAX | SELL | 2021-11-30 | $719K | — | Filing → |
| NVAX | SELL | 2021-11-24 | $2.5M | — | Filing → |